Breakthrough reactions during rapid drug desensitization: Clinical outcome and risk factors
Recently, new diagnostic tools and therapeutic agents have significantly increased the survival rate of cancer patients compared to that in the past. As the number of cancer survivors exposed to multiple courses of chemotherapy increases, more patients become sensitized to chemotherapeutic agents and suffer from hypersensitivity reactions (HSRs).1-3 HSRs to chemotherapeutic agents range from mild cutaneous urticaria to severe reactions, such as life-threatening anaphylaxis, and even death.4 Most HSRs are unpredictable, such that they threaten the safety of patients; moreover, they can be uncontrollable, and severe HSRs limit the effectiveness of chemotherapy, increase hospital costs, and worsen prognosis.
Date: Monday, 11 18, 2019; Speaker: Barton Haynes, M.D., Frederic M. Hanes Professor of Medicine and Immunology, Duke University School of Medicine; Carolyn Coyne, Ph.D., Professor of Pediatrics, University of Pittsburgh; Matthias Gromeier, M.D., Professor of Neurosurgery, Duke University School of Medicine; Adam Zlotnick, Ph.D., Professor of Molecular and Cellular Biochemistry, Indiana University; Malcolm Martin, M.D., Chief, Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases; Lipsett Auditorium of the Clinical Center
Date: Wednesday, 07 17, 2019; Speaker: Mary Kearney, PhD, Head, Translational Research Unite, HIV Dynamics and Replication Program, Center, National Cancer Institute; https://bit.ly/2RyT8Kw
Publication date: Available online 22 June 2019Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Luisa Taylor, Morgan Waller, Jay PortnoyAbstractTelemedicine (TM) involves the use of technology to provide medical services to patients who live at a distance. It can be used asynchronously for interpretation of tests (spirometry, skin tests imaging studies), and for communication of information when the simultaneous presence of provider and patient is unnecessary. Synchronous encounters can be either unscheduled and initiated on-demand by patients or they can be facilitated substitutes for in-perso...
Publication date: Available online 22 June 2019Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Stephen Betschel, Ernie Avilla, Amin Kanani, Monika Kastner, Paul Keith, Karen Binkley, Gina Lacuesta, Rozita Borici-Mazi, Jacquie Badiou, Anne Rowe, William H. Yang, Susan WasermanAbstractBackgroundHAE patients present to the emergency department (ED), where their symptoms are often incorrectly attributed to common allergic and gastrointestinal conditions resulting in major delays in diagnosis and treatment.ObjectiveThe goal of this study was to develop a rapid triage HAE tool for ED settings.Method...
ConclusionOur data support the concept of MDH as a distinct and rare subgroup of DH. The prevalence in our database was 2.5% in the total DH alleged patient population and 0.5% of the demonstrated DH. Skin testing and DPT are mandatory for confirming the diagnosis.
ConclusionLong-term Abatacept therapy is effective in the majority of patients with LRBA deficiency.
In this study, we constructed a dual function nanosystem, copper sulfide nanoplatform loaded with the chemotherapeutic drug docetaxel wrapped by a conjugated polymer-peptide for targeted chemo-phototherapy. The nanoconstruct has been successfully designed with a size of 186.1 ± 5.2 nm, a polydispersity index of 0.18 ± 0.01, and zeta potential of −16.4 ± 0.1 mV. The enhanced uptake and near-infrared-responsive behavior of the nanosystem resulted in efficient drug release, photothermal ablation, effective cytotoxic activity, and potentiated reactive oxygen sp...
Higher intake of gluten early in life is associated with an increased risk of celiac disease (CD) and CD autoimmunity, according to new findings.Reuters Health Information
Rituximab is a chimeric monoclonal anti-CD20 antibody with wide use in cancer (lymphoma) and connective tissue diseases (rheumatoid arthritis, and vasculitis)1. Hypersensitivity reactions to rituximab can range from type I IgE-mediated reaction (urticaria, shortness of breath, hypotension, or anaphylaxis), to cytokine-mediated reaction (fevers, chills, rigors), or a mix of both, thus limiting the use of rituximab as first line therapy for many cases. Desensitization is a new therapeutic approach which can be performed with rituximab to offset these reactions.
Rituximab is a chimeric monoclonal anti-CD20 antibody with wide use in cancer (lymphoma) and connective tissue diseases (rheumatoid arthritis and vasculitis).1 Hypersensitivity reactions to rituximab can range from type I immunoglobulin E (IgE)-mediated reaction (urticaria, shortness of breath, hypotension, or anaphylaxis) to cytokine-mediated reaction (fevers, chills, rigors) or a mix of both, thus limiting the use of rituximab as first-line therapy for many cases. Desensitization is a new therapeutic approach that can be performed with rituximab to offset these reactions.